000163759 001__ 163759
000163759 005__ 20230915090536.0
000163759 0247_ $$2doi$$a10.1080/14737175.2022.2049758
000163759 0247_ $$2pmid$$apmid:35240905
000163759 0247_ $$2ISSN$$a1473-7175
000163759 0247_ $$2ISSN$$a1744-8360
000163759 0247_ $$2altmetric$$aaltmetric:124041431
000163759 037__ $$aDZNE-2022-00498
000163759 041__ $$aEnglish
000163759 082__ $$a610
000163759 1001_ $$aScuteri, Damiana$$b0
000163759 245__ $$aReal world considerations for newly approved CGRP receptor antagonists in migraine care.
000163759 260__ $$aAbingdon$$bTaylor & Francis Group$$c2022
000163759 3367_ $$2DRIVER$$aarticle
000163759 3367_ $$2DataCite$$aOutput Types/Journal article
000163759 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1650618325_26123$$xReview Article
000163759 3367_ $$2BibTeX$$aARTICLE
000163759 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163759 3367_ $$00$$2EndNote$$aJournal Article
000163759 520__ $$aMigraine is the leading cause of years lived with disability in people under 50. Electrophysiological phenomena at the basis of prodromal and headache attack phases and of chronification processes involve calcitonin-gene related peptide (CGRP) as a fundamental player become a game changer of migraine pharmacotherapy.The purpose of the present review is to retrace fundamental stages of CGRP from its discovery to the role in migraine pathogenesis and therapy to underscore the change of paradigm offered by the newly approved small molecules to antagonize CGRP receptor, the gepants. In particular, the development of this new class is gone over from the initial synthesis of C-terminus truncated CGRP antagonists to the development of the first generation of gepants ending with Zavegepant that can be considered the third generation.The history of CGRP in migraine draws the successful road to follow for key signaling pathways of modulation of nociceptive facilitation by diencephalic and brainstem nuclei, including dopaminergic neurotransmission, orexin A and the large-conductance calcium-activated potassium (BKCa) and ATP-sensitive potassium (KATP) channels also investigating the potential of essential oils and the role of polymorphisms. Real-world post marketing long-term data are needed for gepants.
000163759 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x0
000163759 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163759 650_7 $$2Other$$aAtogepant
000163759 650_7 $$2Other$$aCGRP antagonists
000163759 650_7 $$2Other$$agepants
000163759 650_7 $$2Other$$amigraine
000163759 650_7 $$2Other$$arimegepant
000163759 650_7 $$2Other$$aubrogepant
000163759 650_7 $$2Other$$avazegepant
000163759 650_7 $$2NLM Chemicals$$aCalcitonin Gene-Related Peptide Receptor Antagonists
000163759 650_7 $$2NLM Chemicals$$aReceptors, Calcitonin Gene-Related Peptide
000163759 650_7 $$0JHB2QIZ69Z$$2NLM Chemicals$$aCalcitonin Gene-Related Peptide
000163759 650_2 $$2MeSH$$aCalcitonin Gene-Related Peptide
000163759 650_2 $$2MeSH$$aCalcitonin Gene-Related Peptide Receptor Antagonists: pharmacology
000163759 650_2 $$2MeSH$$aCalcitonin Gene-Related Peptide Receptor Antagonists: therapeutic use
000163759 650_2 $$2MeSH$$aHeadache: drug therapy
000163759 650_2 $$2MeSH$$aHumans
000163759 650_2 $$2MeSH$$aMigraine Disorders: drug therapy
000163759 650_2 $$2MeSH$$aMigraine Disorders: metabolism
000163759 650_2 $$2MeSH$$aReceptors, Calcitonin Gene-Related Peptide
000163759 7001_ $$aTonin, Paolo$$b1
000163759 7001_ $$0P:(DE-2719)2010732$$aNicotera, Pierluigi$$b2$$udzne
000163759 7001_ $$aBagetta, Giacinto$$b3
000163759 7001_ $$aCorasaniti, Maria Tiziana$$b4
000163759 773__ $$0PERI:(DE-600)2090856-8$$a10.1080/14737175.2022.2049758$$gVol. 22, no. 3, p. 221 - 230$$n3$$p221 - 230$$tExpert review of neurotherapeutics$$v22$$x1473-7175$$y2022
000163759 909CO $$ooai:pub.dzne.de:163759$$pVDB
000163759 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2010732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000163759 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x0
000163759 9141_ $$y2022
000163759 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000163759 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000163759 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-15
000163759 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-15
000163759 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-15
000163759 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-15
000163759 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXPERT REV NEUROTHER : 2021$$d2022-11-15
000163759 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-15
000163759 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-15
000163759 9201_ $$0I:(DE-2719)1013003$$kAG Bano$$lAging and neurodegeneration$$x0
000163759 9201_ $$0I:(DE-2719)1030000$$kScientific board$$lScientific board$$x1
000163759 980__ $$ajournal
000163759 980__ $$aVDB
000163759 980__ $$aI:(DE-2719)1013003
000163759 980__ $$aI:(DE-2719)1030000
000163759 980__ $$aUNRESTRICTED